Jul 24, 2020
Sorrento Enters Into Letter Of Intent To Acquire SmartPharm And Develop Pipeline Of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies To Treat COVID-19 and Cancer Therapeutics
Sep 07, 2018
Scilex Presents ZTlido(TM) Data on Superior Adhesion over Lidocaine Patch Formulation
Nov 14, 2017
Scilex Pharmaceuticals, Sorrento Therapeutics' Subsidiary, Files Marketing Authorization Application In The European Union For ZTlido(TM)
Oct 02, 2017
Sorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors
Sep 19, 2017
Sorrento Therapeutics, Inc. To Present At Cantor Global Healthcare Conference (09/25/17 - 2:25 PM ET)
Sep 12, 2017
FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido(TM); PDUFA Date Set For February 28, 2018
Sep 08, 2017
Sorrento Therapeutics, Inc. To Present At 19th Rodman And Renshaw Global Investment Conference (09/11/17 - 17:30 ET)
Aug 29, 2017
Sorrento Therapeutics, Inc. Submits NDA For ZTlido(TM) Next-Generation Lidocaine Patch
Jun 29, 2017
Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain
Jun 26, 2017
Semnur Pharmaceuticals, Inc., Announces Successful Phase 1 / 2 Trial in Patients with Radicular Pain for Its Lead Product, SP-102
Jun 14, 2017
Sorrento Therapeutics Announces Dismissal Of Lawsuits
Jun 14, 2017
Sorrento Therapeutics' Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido(TM)
Jun 13, 2017
Sorrento Therapeutics Contributes to the Formation of Celularity, Inc.